Pfizer and Innovent Biologics have signed a cancer drug development partnership worth up to $10.5 billion, covering 12 ...

Pfizer (NYSE:PFE) has entered a new alliance with Sarah Cannon Research Institute to accelerate oncology clinical trials and ...

Innovent Biologics rose as much as 10%, after entering a strategic global licensing and collaboration agreement with Pfizer to develop oncology medicines.

Involving up to 12 antibody drugs, the alliance is the latest broad partnership between Chinese biotech and a multinational pharmaceutical company.

Pfizer and its partners have granted Rigel Pharmaceuticals an exclusive license to commercialize VEPPANU (vepdegestrant), the ...

Pfizer Inc. (NYSE: PFE) and Innovent Biologics, Inc. (01801.HK), today announced the companies have entered into a strategic global licensing and collaboration agreement for the research and ...

Pfizer and Innovent strike a global cancer-drug partnership as Chinese biotech licensing momentum accelerates.

China's Innovent Biologics and U.S. pharma giant Pfizer have agreed to a global licensing and collaboration deal worth up to ...

Shares of Sangamo Therapeutics have plummeted more than 56% over the past few days after Pfizer announced it had terminated its partnership to develop an investigational gene therapy product to treat ...

Call it a case of good chemistry: Acepodia, a biotech based on Nobel Prize-winning science, is entering into a new partnership with Pfizer’s Ignite program to support development of the biotech's ...

KIRKLAND, QC, Aug. 19, 2025 /CNW/ - On World Humanitarian Day, Pfizer Canada is proud to mark 30 years of partnership with Health Partners International of Canada (HPIC), a collaboration that has ...

Management provided a 2026 adjusted total revenue target of $230 million to $270 million, including $35 million to $45 million of Nuvaxovid product sales under existing orders, $40 million to $50 ...